Literature DB >> 16228280

Efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of sarcoptic mange and otoacariosis in dogs: results af a European field study.

K Krieger1, J Heine2, P Dumont3, K Hellmann4.   

Abstract

Efficacy and safety of treatment with imidacloprid 10%+moxidectin 2.5% spot-on (Advocate, Advantage multi; Bayer AG, Leverkusen, Germany) were tested in dogs naturally infested with Sarcoptes scabiei or Otodectes cynotis in a multi-centre, controlled, randomized, blinded field study conducted in France, Germany, Albania and the UK. The study was performed according to a non-inferiority design to demonstrate that the efficacy of imidacloprid/moxidectin spot-on was not inferior to that of a control product containing selamectin (Stronghold spot-on; Pfizer). All Sarcoptes-infested dogs were topically treated twice (days 0 and 28) with the dosage recommended by the respective manufacturer (27 dogs with imidacloprid/moxidectin, 26 with selamectin). All Otodectes-infested dogs were treated on day 0 (35 dogs with imidacloprid/moxidectin, 34 with selamectin), and only those still positive on day 28 received a second treatment. Parasitological cure rate in Sarcoptes-infested dogs was 100% for both treatments, while parasitological cures rates in the Otodectes-infested dogs at day 28 and day 56 were 68.6 and 85.7% with imidacloprid/moxidectin, and 64.7 and 88.2% with Stronghold. Non-inferiority of Advocate was confirmed statistically. Clinical assessment of skin lesion scores at day 56 showed that with either product >96% of the dogs treated against sarcoptic mange were improved or cured, the difference between the groups being non-significant. On the basis of a final clinical assessment of lesion scores, 80% of the dogs treated with imidacloprid/moxidectin against otoacariosis and 85.3% of those treated with selamectin were rated cured or improved. Only three mild, possibly drug-related adverse reactions were observed among alI treated animals (two in the imidacloprid/moxidectin group, one in the selamectin group). It is concluded that imidacloprid/moxidectin spot-on is an effective and safe treatment for sarcoptic mange and otoacariosis in the dog.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16228280     DOI: 10.1007/s00436-005-1449-9

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  9 in total

1.  Efficacy and safety of the combination imidacloprid 10 % / moxidectin 1.0 % spot-on (Advocate(®) spot-on for small cats and ferrets) in the treatment of ear mite infection (Otodectes cynotis) in ferrets.

Authors:  Christophe Le Sueur; Sophie Bour; Roland Schaper
Journal:  Parasitol Res       Date:  2011-08       Impact factor: 2.289

2.  A systematic review of moxidectin as a treatment for parasitic infections in mammalian species.

Authors:  Andrea L Schraven; Hayley J Stannard; Julie M Old
Journal:  Parasitol Res       Date:  2021-02-22       Impact factor: 2.289

3.  Neem seed extract shampoo, Wash Away Louse, an effective plant agent against Sarcoptes scabiei mites infesting dogs in Egypt.

Authors:  Fathy Abdel-Ghaffar; Saleh Al-Quraishy; Hassan Sobhy; Margit Semmler
Journal:  Parasitol Res       Date:  2008-09-04       Impact factor: 2.289

4.  Efficacy of afoxolaner plus milbemycin oxime and afoxolaner alone as treatment for sarcoptic mange in naturally infested dogs.

Authors:  Camilo Romero-Núñez; Linda G Bautista-Gómez; Galia Sheinberg; Alberto Martín-Cordero; Ariadna Flores-Ortega; Rafael Heredia-Cárdenas
Journal:  Can J Vet Res       Date:  2020-07       Impact factor: 1.310

Review 5.  Treatment of MDR1 mutant dogs with macrocyclic lactones.

Authors:  Joachim Geyer; Christina Janko
Journal:  Curr Pharm Biotechnol       Date:  2012-05       Impact factor: 2.837

6.  Treatment of canine sarcoptic mange with afoxolaner (NexGard®) and afoxolaner plus milbemycin oxime (NexGard Spectra®) chewable tablets: efficacy under field conditions in Portugal and Germany.

Authors:  Verena Hampel; Martin Knaus; Jürgen Schäfer; Frederic Beugnet; Steffen Rehbein
Journal:  Parasite       Date:  2018-12-05       Impact factor: 3.000

7.  Development of advantus(imidacloprid) soft chewable tablets for the treatment of Ctenocephalides felis infestations on dogs.

Authors:  Tariq Qureshi; William R Everett; Kathleen G Palma
Journal:  Parasit Vectors       Date:  2015-08-04       Impact factor: 3.876

8.  Efficacy of afoxolaner in a clinical field study in dogs naturally infested with Sarcoptes scabiei.

Authors:  Frédéric Beugnet; Christa de Vos; Julian Liebenberg; Lénaïg Halos; Diane Larsen; Josephus Fourie
Journal:  Parasite       Date:  2016-06-17       Impact factor: 3.000

9.  Assessment of afoxolaner efficacy against Otodectes cynotis infestations of dogs.

Authors:  Doug Carithers; Jordan Crawford; Christa de Vos; Alta Lotriet; Josephus Fourie
Journal:  Parasit Vectors       Date:  2016-12-09       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.